Schneeweiss A
Pediatr Cardiol. 1988;9(2):109-15. doi: 10.1007/BF02083709.
Angiotensin-converting enzyme inhibitors are potent vasodilators acting by inhibition of production of the vasoconstrictor angiotensin II. In adults, they are used for treatment of systemic hypertension and congestive heart failure and investigated for treatment of primary pulmonary hypertension. In infants and children, saralasin and captopril were found to be useful in treatment of systemic arterial hypertension, especially when associated with high plasma renin activity. Captopril has failed in the treatment of congestive heart failure associated with complex congenital heart diseases and in most cases of primary pulmonary hypertension. It has a clear beneficial effect in coarctation of the aorta and may have such an effect in endomyocardial diseases and ventricular septal defect. In adults, serious side effects have limited the use of captopril. New converting enzyme inhibitors, devoid of a sulfhydryl group, are expected to have a better safety profile.
血管紧张素转换酶抑制剂是强效血管扩张剂,通过抑制血管收缩剂血管紧张素II的产生发挥作用。在成人中,它们用于治疗系统性高血压和充血性心力衰竭,并用于原发性肺动脉高压的治疗研究。在婴儿和儿童中,发现沙拉新和卡托普利可用于治疗系统性动脉高血压,尤其是与高血浆肾素活性相关时。卡托普利在治疗与复杂先天性心脏病相关的充血性心力衰竭以及大多数原发性肺动脉高压病例中均告失败。它对主动脉缩窄有明显的有益作用,对心肌内膜疾病和室间隔缺损可能也有这样的作用。在成人中,严重的副作用限制了卡托普利的使用。不含巯基的新型转换酶抑制剂有望具有更好的安全性。